Thomas Leggett
Directeur Financier/CFO chez STOKE THERAPEUTICS, INC.
Fortune : 15 185 $ au 31/05/2024
Profil
Thomas Leggett is an Independent Director at Research Alliance Corp.
II, an Independent Non-Executive Director at Clover Biopharmaceuticals Ltd., and the Chief Financial & Accounting Officer at Stoke Therapeutics, Inc. He previously worked as an Executive Director at UBS Securities LLC from 2009 to 2015, Treasurer & Head-Finance Business Development at Purdue Pharma LP in 2016, Chief Financial Officer & Senior VP-Finance at Axcella Health, Inc. from 2017 to 2019, and Chief Financial & Accounting Officer at Black Diamond Therapeutics, Inc. from 2019 to 2021.
He also served as the Chief Financial Officer at Affinia Therapeutics, Inc. from 2021 to 2024.
Mr. Leggett obtained his undergraduate degree from The Trustees of Columbia University in The City of New York in 1999 and an MBA from The Wharton School of the University of Pennsylvania in 2004.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/04/2024 | 300 750 ( 0,02% ) | 15 185 $ | 31/05/2024 |
Postes actifs de Thomas Leggett
| Sociétés | Poste | Début |
|---|---|---|
| RESEARCH ALLIANCE CORP. II | Directeur/Membre du Conseil | 01/02/2021 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Directeur/Membre du Conseil | 19/04/2021 |
| STOKE THERAPEUTICS, INC. | Directeur Financier/CFO | 07/05/2024 |
Anciens postes connus de Thomas Leggett
| Sociétés | Poste | Fin |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Directeur Financier/CFO | 30/04/2024 |
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur Financier/CFO | 16/11/2021 |
| AXCA HEALPAR | Directeur Financier/CFO | 30/08/2019 |
Purdue Pharma LP
 Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Treasurer | 01/12/2016 |
UBS Securities LLC
 UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Directeur/Membre du Conseil | 01/05/2015 |
Formation de Thomas Leggett
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AXCA HEALPAR | Health Technology |
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
UBS Securities LLC
UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Finance |
Research Alliance Corp. II
 Research Alliance Corp. II Financial ConglomeratesFinance Research Alliance Corp. II operates as a blank check company. The company was founded by Peter Kolchinsky, Matthew Hammond and Tess Cameron on July 17, 2020 and is headquartered in Las Vegas, NV. | Finance |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
